3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Allie Danziger of Ampersand, Wesley Okeke of CUBIO, and Libby Covington of The Craig Group. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to future of work — recently making headlines in Houston innovation.


Allie Danziger, co-founder and CEO of Ampersand Professionals

Allie Danziger, is bridging the gap between the next generation — and their future employers. Photo courtesy of Ampersand

Allie Danziger has established herself as an expert in the future of work and all things Gen Z in the workplace. The founder of an internship matching and training platform called Ampersand, she's contributed numerous articles on related topics, including "The Great Resignation," which is affecting the workforce across industries. It's also something her platform can address, as she explains on the Houston Innovators Podcast.

"When someone leaves, other people take on that work. If you don't hire proper support for the people still there, you see the trickle. You see more and more people leave, because they are just burnt out," Danziger says. "By hiring interns or entry-level support, it shows the employees still there that you've got them."

Danziger shares more on Ampersand's future and navigating the Gen Z workforce on the podcast. Click here to read more and stream the episode.

Wesley Okeke, CEO of CUBIO Innovation Center

Wesley Okeke has established some much-needed new lab space in the Texas Medical Center. Photo courtesy

Look alive, Houston biotech innovators. CUBIO Innovation Center has some new space available for you. What originated as mostly coworking space, CUBIO has pivoted to provide more lab space for early stage biotech startups. The latest edition to CUBIO in the Texas Medical Center? A brand new wet lab.

“We have all the necessary equipment for a fully functioning biotech lab,” Okeke tells InnovationMap.

"For those working with cell culture, the dry lab provides almost no resources or infrastructure for you to build it out," he continues. "A wet lab brings in the necessary equipment and environment to be successful in developing pharmaceuticals, drug delivery devices, whatever you need in the biotech space.” Click here to read more.

Libby Covington, partner at The Craig Group

What should Houston startups know about marketing? Photo courtesy

How should startups be marketing themselves to venture capitalists? Libby Covington has some advice in a guest article for InnovationMap — from making your marketing plan and catering specifically to VCs.

"It is important to focus on efficient top line revenue growth as a business grows and scales," she writes. "Digital marketing is an important part of the overall growth plan, and should not be overlooked. The clock starts ticking on profitability growth once a business owner partners with investors. Make sure your business has an effective plan to meet the goals set out." Click here to read more.

Houston has some much-needed new lab space in the Texas Medical Center. Photo courtesy of CUBIO

Exclusive: Houston biotech coworking spot expands with new wet lab space

ready to rent

While Houston has been recognized as an emerging hub for life sciences, access to lab space is a huge factor in that equation — and one where the city has room for improvement.

CUBIO Innovation Center, located in the heart of the Texas Medical Center, has witnessed that first hand. First opening as a larger coworking concept, CEO Wesley Okeke says it was the smaller lab space that was booked every day. CUBIO pivoted and redistributed their operations to offer more dry lab space to its tenants. Now, the organization is ready to reach the next stage by introducing a new wet lab that opens doors for biotech innovators who need specific infrastructure, equipment, and environment.

“We have all the necessary equipment for a fully functioning biotech lab,” Okeke tells InnovationMap.

"For those working with cell culture, the dry lab provides almost no resources or infrastructure for you to build it out," he continues. "A wet lab brings in the necessary equipment and environment to be successful in developing pharmaceuticals, drug delivery devices, whatever you need in the biotech space.”

The new space can support 15 early stage biotech startups. Photo courtesy of CUBIO

Most of Houston's wet lab space is housed in academic or health care institutions. Getting into those labs can be competitive and complicated, especially when it comes to intellectual property. CUBIO wanted to offer an alternative for early stage biotech teams working on a tight budget and not looking for a long-term commitment.

“When it comes to finding wet lab space, it’s almost nonexistent," Okeke says. "There are a very few out there, but there are very few considering the ecosystem of biotech research in Houston.”

Okeke says CUBIO has seen interest from out-of-town startups looking for space — and not being able to find it without building it themselves.

"We have created what we call lab offices, which could be individual labs, but we have a main area with all our equipment," he says.

And the new space has room to grow. Right now, CUBIO can support 15 companies in its space. With potential to expand on its current sixth floor and to the fifth floor as well, that could grow to a capacity of 50 companies.

Monthly rent starts at $400 for a workbench and up to $950 for a private office and a workbench in the lab. All of CUBIO's memberships options include incubation support from the team and its network of mentors and experts.

“My personal dream and vision is to help these startups in Houston get what they need — get the resources they need and the support they need to launch," Okeke says.

The CUBIO team offers incubation support for its tenant startups. Photo courtesy of CUBIO

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston scientists named winners of prestigious Hill Prizes 2026

prized research

Five Houston scientists were recognized for their "high-risk, high-reward ideas and innovations" by Lyda Hill Philanthropies and the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

The 2026 Hill Prizes provide seed funding to top Texas researchers. This year's prizes were given out in seven categories, including biological sciences, engineering, medicine, physical sciences, public health and technology, and the new artificial intelligence award.

Each recipient’s institution or organization will receive $500,000 in direct funding from Dallas-based Lyda Hill Philanthropies. The organization has also committed to giving at least $1 million in discretionary research funding on an ad hoc basis for highly-ranked applicants who were not selected as recipients.

“It is with great pride that I congratulate this year’s Hill Prizes recipients. Their pioneering spirit and unwavering dedication to innovation are addressing some of the most pressing challenges of our time – from climate resilience and energy sustainability to medical breakthroughs and the future of artificial intelligence,” Lyda Hill, founder of Lyda Hill Philanthropies, said in a news release.

The 2026 Houston-area recipients include:

Biological Sciences: Susan M. Rosenberg, Baylor College of Medicine

Rosenberg and her team are developing ways to fight antibiotic resistance. The team will use the funding to screen a 14,000-compound drug library to identify additional candidates, study their mechanisms and test their ability to boost antibiotic effectiveness in animal models. The goal is to move toward clinical trials, beginning with veterans suffering from recurrent infections.

Medicine: Dr. Raghu Kalluri, The University of Texas MD Anderson Cancer Center

Kalluri is developing eye drops to treat age-related macular degeneration (AMD), the leading cause of vision loss globally. Kalluri will use the funding to accelerate studies and support testing for additional ocular conditions. He was also named to the National Academy of Inventors’ newest class of fellows last month.

Engineering: Naomi J. Halas, Rice University

Co-recipeints: Peter J. A. Nordlander and Hossein Robatjazi, Rice University

Halas and her team are working to advance light-driven technologies for sustainable ammonia synthesis. The team says it will use the funding to improve light-driven catalysts for converting nitrogen into ammonia, refine prototype reactors for practical deployment and partner with industry collaborators to advance larger-scale applications. Halas and Nordlander are co-founders of Syzygy Plasmonics, and Robatjazi serves as vice president of research for the company.

The other Texas-based recipients include:

  • Artificial Intelligence: Kristen Grauman, The University of Texas at Austin
  • Physical Sciences: Karen L. Wooley, Texas A&M University; Co-Recipient: Matthew Stone, Teysha Technologies
  • Public Health: Dr. Elizabeth C. Matsui, The University of Texas at Austin and Baylor College of Medicine
  • Technology: Kurt W. Swogger, Molecular Rebar Design LLC; Co-recipients: Clive Bosnyak, Molecular Rebar Design, and August Krupp, MR Rubber Business and Molecular Rebar Design LLC

Recipients will be recognized Feb. 2 during the TAMEST 2026 Annual Conference in San Antonio. They were determined by a committee of TAMEST members and endorsed by a committee of Texas Nobel and Breakthrough Prize Laureates and approved by the TAMEST Board of Directors.

“On behalf of TAMEST, we are honored to celebrate the 2026 Hill Prizes recipients. These outstanding innovators exemplify the excellence and ambition of Texas science and research,” Ganesh Thakur, TAMEST president and a distinguished professor at the University of Houston, added in the release. “Thanks to the visionary support of Lyda Hill Philanthropies, the Hill Prizes not only recognize transformative work but provide the resources to move bold ideas from the lab to life-changing solutions. We are proud to support their journeys and spotlight Texas as a global hub for scientific leadership.”

Investment bank opens new Houston office focused on energy sector

Investment bank Cohen & Co. Capital Markets has opened a Houston office to serve as the hub of its energy advisory business and has tapped investment banking veteran Rahul Jasuja as the office’s leader.

Jasuja joined Cohen & Co. Capital Markets, a subsidiary of financial services company Cohen & Co., as managing director, and head of energy and energy transition investment banking. Cohen’s capital markets arm closed $44 billion worth of deals last year.

Jasuja previously worked at energy-focused Houston investment bank Mast Capital Advisors, where he was managing director of investment banking. Before Mast Capital, Jasuja was director of energy investment banking in the Houston office of Wells Fargo Securities.

“Meeting rising [energy] demand will require disciplined capital allocation across traditional energy, sustainable fuels, and firm, dispatchable solutions such as nuclear and geothermal,” Jasuja said in a news release. “Houston remains the center of gravity where capital, operating expertise, and execution come together to make that transition investable.”

The Houston office will focus on four energy verticals:

  • Energy systems such as nuclear and geothermal
  • Energy supply chains
  • Energy-transition fuel and technology
  • Traditional energy
“We are making a committed investment in Houston because we believe the infrastructure powering AI, defense, and energy transition — from nuclear to rare-earth technology — represents the next secular cycle of value creation,” Jerry Serowik, head of Cohen & Co. Capital Markets, added in the release.

---

This article originally appeared on EnergyCaptialHTX.com.

MD Anderson makes AI partnership to advance precision oncology

AI Oncology

Few experts will disagree that data-driven medicine is one of the most certain ways forward for our health. However, actually adopting it comes at a steep curve. But what if using the technology were democratized?

This is the question that SOPHiA GENETICS has been seeking to answer since 2011 with its universal AI platform, SOPHiA DDM. The cloud-native system analyzes and interprets complex health care data across technologies and institutions, allowing hospitals and clinicians to gain clinically actionable insights faster and at scale.

The University of Texas MD Anderson Cancer Center has just announced its official collaboration with SOPHiA GENETICS to accelerate breakthroughs in precision oncology. Together, they are developing a novel sequencing oncology test, as well as creating several programs targeted at the research and development of additional technology.

That technology will allow the hospital to develop new ways to chart the growth and changes of tumors in real time, pick the best clinical trials and medications for patients and make genomic testing more reliable. Shashikant Kulkarni, deputy division head for Molecular Pathology, and Dr. J. Bryan, assistant professor, will lead the collaboration on MD Anderson’s end.

“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” Dr. Donna Hansel, division head of Pathology and Laboratory Medicine at MD Anderson, said in a press release. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”

SOPHiA GENETICS is based in Switzerland and France, and has its U.S. offices in Boston.

“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” Dr. Philippe Menu, chief product officer and chief medical officer at SOPHiA GENETICS, added in the release. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”

View All Listings